Alpha Cognition to begin its pivotal clinical trial to treat symptoms of Alzheimer’s disease

5:50
 
Share
 

Manage episode 302941728 series 2891889
By Proactive Investors. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF) CEO Michael McFadden tells Proactive the Vancouver, Canada-based biopharmaceutical company focused on neurodegenerative disorders is will soon initiate its pivotal trial to treat the symptoms associated with Alzheimer’s disease in 3Q of this year. McFadden says top-line results from its lead drug ALPHA-1062 are targeted for release in Q1 of 2022, putting it on track for an approval in 2023.

1858 episodes